Tweets
RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by UCB.
All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
25 minutes 30 seconds ago
RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by Eli Lilly and Company.
All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
54 minutes 29 seconds ago
ACR 2026 RheumNow Day 2 Recap https://t.co/YNEmDFBdzv
Links:
Dr. John Cush @RheumNow ( View Tweet )
55 minutes 3 seconds ago
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by UCB.
All content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
1 hour 54 minutes ago
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 hours ago
SPACE, 67 axSpA patients over about 2 years: low dose CT was 2.3 to 2.7 times more responsive to spinal change than mSASSS, followed by MRI bone spurs (2.1). Key finding: low dose CT was the most responsive modality, and absolute progression was low with all methods. @rheumnow
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 hours 57 minutes ago
LLM extraction from 488 PsA records (Columbia): 42.6% met full CASPAR criteria and 43.2% had inflammatory features without full CASPAR. Key finding: CASPAR features were extracted at scale, while cDAPSA was documented in 4.9% of records. @rheumnow #ACR26 Abstract#1348
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
3 hours 16 minutes ago
JAKi vs TNFi in higher-CV-risk RA: target trial emulation of 17607 matched pairs found MACE HR 1.02, but higher mortality (HR 1.21) and HF admission (HR 1.11). Findings refine results from ORAL Surveillance and support individualized JAKi agent selection #1900 @Rheumnow #ACR26 https://t.co/uDuOCPa6bf
Mrinalini Dey @DrMiniDey ( View Tweet )
3 hours 16 minutes ago
Fibromyalgia was present in 9.3% of 151 SpA patients, with ASDAS CRP 3.7 vs 2.2 without it. Key finding: fibromyalgia was associated with higher disease activity and poorer function, and the six item FiRST had a negative predictive value of 98.4%. @rheumnow #ACR26 Abstract#1354
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
3 hours 17 minutes ago
Nociplastic pain in axSpA (OHSU): 32.5% of 83 patients had FSQ of 13 or more. FSQ correlated with ASDAS CRP (r 0.53) and lower pressure pain thresholds. Key finding: nociplastic features were common and associated with higher disease activity scores and female sex. Watch my video
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
3 hours 17 minutes ago
Respiratory infections: a potential missing link in RA-ILD development
#ACR26 Abstract 1737: Respiratory infections were associated with subsequent RA-ILD, particularly non-fibrotic disease.
A new perspective on infection prevention in RA.
@RheumNow https://t.co/ObzgmwguV0
Licia Mota @Mota_licia_reum ( View Tweet )
3 hours 17 minutes ago
Are neutrophils the missing piece of the gout puzzle?
#ACR26 Abstract 1646: Transcriptomic profiling identified 25 genes associated with tophi, highlighting neutrophil degranulation.
Perhaps the story of gout doesn’t end with urate crystals.
@RheumNow https://t.co/CqKEXRFrDH
Licia Mota @Mota_licia_reum ( View Tweet )
3 hours 17 minutes ago
Valenzuela et al. 34 patient basket study. AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells, in Combination with Rituximab. Treatment refractory, active rheumatic diseases. Encouraging efficacy data, safety looked good also. @RheumNow #ACR26 Abstr#1899 https://t.co/gA1Ggi0blQ
Richard Conway @RichardPAConway ( View Tweet )
3 hours 17 minutes ago
KIds age 15 or older double missed apts for health visits
Vs younger kids
Which levels around age 20
More missed apts if
Deprivation
Minorities esp blacks
LOndon NHS Rheum
We can improve 15 to 20 yrs services to help visits /health #1911
#ACR26 #ACRBest @ACRheum @RheumNow https://t.co/01rXfGPeWj
Links:
Janet Pope @Janetbirdope ( View Tweet )
3 hours 17 minutes ago
Could tirzepatide offer vascular benefits beyond GLP-1 RAs in RA?
#ACR26: In 7,944 matched patients with RA and T2D, tirzepatide was associated with lower thromboembolic risk (HR 0.84) and mortality (HR 0.54).
Promising observational data, not proof of causality.
@RheumNow https://t.co/FnCOoe6F7e
Licia Mota @Mota_licia_reum ( View Tweet )
3 hours 17 minutes ago